Emmyco

Emmyon is a biotechnology company focused on developing small molecule therapeutics to improve muscle health and treat muscle-related disorders. Founded as a spin-off from the University of Iowa, the company leverages research into natural compounds like ursolic acid and tomatidine to identify pathways that regulate muscle mass and function. Their primary focus is on inhibiting the ATF4 (Activating Transcription Factor 4) pathway, which plays a critical role in muscle wasting associated with aging, injury, and chronic disease. Emmyon's pipeline includes candidates aimed at muscle atrophy, sarcopenia, and metabolic health conditions such as obesity and type 2 diabetes. The company has received significant funding through NIH SBIR grants to advance its discovery programs and pre-clinical studies. By targeting the molecular drivers of muscle loss, Emmyon aims to provide new treatment options for patients with chronic diseases and aging-related decline.